The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

Volumn , Issue , 2013, Pages 313-318

  Smith, Catherine C ^a   Shah, Neil P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZOTHIAZOLE DERIVATIVE; CARBANILAMIDE DERIVATIVE; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUIZARTINIB; TARGET OF RAPAMYCIN KINASE;

ANTAGONISTS AND INHIBITORS; CELL CYCLE; DRUG EFFECTS; HUMAN; LEUKEMIA, MYELOID, ACUTE; MITOSIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOTHIAZOLES; CELL CYCLE; FMS-LIKE TYROSINE KINASE 3; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, ACUTE; MITOSIS; MOLECULAR TARGETED THERAPY; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84979796721     PISSN: None     EISSN: 15488756     Source Type: Journal    
DOI: 10.1200/EdBook_AM.2013.33.313     Document Type: Review

References (0)